A rejuvenated R&D shop has given Bayer a spate of potential blockbusters, and CEO Marijn Dekkers wants to see more where that came from. The German drugmaker is planning to substantially increase its research budget over the next three years and set aside a boatload of cash for M&A.

…read more

Source: Bayer plans to ratchet up its R&D spend and chase down some deals


0 No comments